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Abstract 
Aims: To determine, in subjects with painful temporomandibular disorders 
(TMD), whether baseline SF-12 Physical Component Summary (PCS), SF-12 
Mental Component Summary (MCS) and Jaw Functional Limitation Scale (JFLS) 
predict persistent TMD pain measured by Characteristic Pain Intensity (CPI) 
scores after 9 years.  
Methods: 258 subjects with painful TMD diagnoses and CPI>0 completed 
baseline SF-12 Health-Related Quality of Life (HRQoL) and JFLS questionnaires. 
After 9 years, they were reevaluated for painful TMD diagnoses and completed 
the CPI questionnaire. Univariable and multivariable linear regression adjusted 
for age and sex examined the relationship between baseline predictors and 
follow-up CPI.  
Results: After 9 years, 186 (72%) had persistent TMD pain. Baseline PCS and 
JFLS, but not MCS, presented weak linear relationships with follow-up CPI. One 
SD (9.0) increase in baseline PCS was associated with a 4.9-point decrease in 
follow-up CPI (SE=1.2, p<0.001), or 5.7% of the follow-up CPI score range. One 
SD (1.4) increase in baseline JFLS was associated with a 5.0-point increase in 
follow-up CPI scores (SE=1.2, p<0.001), or 5.8% of the follow-up CPI score 
range. In the 3-predictor multivariable model, follow-up CPI change predicted by 
1 SD increase in baseline scores was of -4.7 (SE=1.3, p<0.001) for PCS, and 3.9 
points (SE=1.2, p=0.002) for JFLS.  
Conclusions: In subjects with TMD pain, baseline PCS and JFLS, but not MCS, 
were statistically significant predictors of CPI at a 9-year follow-up. However, the 
magnitude of the effects is small and below the 10-20% minimum change in pain 
intensity recommended for clinical significance.  
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Introduction 
Temporomandibular disorders (TMD) consist of different clinical disorders 
involving the masticatory muscles, the temporomandibular joints (TMJ) and the 
associated structures. 1  Painful TMD is the most frequent reason patients seek 
treatment and is estimated to affect approximately 10% of the adult population.2 
It has been reported that the majority of TMD cases tend to remit or present as 
recurrent, but approximately 15% of the patients who seek care progress to 
chronic TMD pain3 , often defined as pain lasting longer than 3 months. 4  Causal 
factors for the persistence of TMD pain are not clear, but research has 
demonstrated that psychosocial factors are significantly higher in TMD patients 
than pain-free controls5-8 and are associated with chronic TMD pain.9-11 Prior 
studies have suggested that biopsychosocial factors including poor general 
health can predict onset of chronic pain conditions such as widespread pain12 
and other musculoskeletal disorders13-17 including orofacial pain and TMD.18-21  
 
Health related quality of life (HRQoL) measures have been used to assess the 
individual’s functioning and disease burden for many chronic physical conditions 
including headaches,22 arthritis,23,24 back pain,15,23,24 and TMD. 6,25,26  The 12-item 
Short Form Health Survey (SF-12),27,28 is a commonly used HRQoL 
questionnaire, derived from the 36-item version, SF-36.29 The SF-12 and the SF-
36 evaluate 8 health domains (physical functioning, role physical, bodily pain, 
general health, mental health, role emotional, social functioning and vitality), 
which can be scored as separate sub-scales. The SF-12 and SF-36 also yield 2 
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summary scores: the Physical Component Summary (PCS) and the Mental 
Component Summary (MCS). SF-12 and SF-36 scores have been shown to 
differ significantly between patients and healthy controls for migraine,30,31 
fibromyalgia,31 and TMD.25 SF-12 scores have been reported to have a dose-
response relationship according to the severity of various chronic health 
conditions.32 In a multivariable model, the SF-12 bodily pain and general health 
sub-scales were among the 11 best predictors for new-onset TMD out of 202 
putative risk factors evaluated in a large cohort study. 33  To date, no studies have 
evaluated the capacity of SF-12 scores to predict pain outcomes in TMD 
subjects. Simple assessment instruments with predictive value for identifying 
patients at risk for persistent TMD pain are highly desirable. 
 
According to the Initiative on Methods, Measurement, and Pain Assessment in 
Clinical Trials (IMMPACT),34 there are 2 broad areas of assessment for physical 
functioning and, more generally, HRQoL: generic global measures, such as the 
SF-12, and disease-specific measures. The Jaw Functional Limitation Scale 
(JFLS)35 assesses TMD-specific physical functioning. The JFLS is a DC-TMD36 
Axis II instrument and its scores have been found to be significantly higher in 
TMD cases compared to pain-free controls in a large case-control study.37  
 
The aim of this study is to determine, in adults with baseline TMD pain, whether 
baseline PCS, MCS and JFLS scores predict persistent TMD pain at a 9-year 
follow-up. 
  3 
Methods 
Study sample 
This study’s baseline and follow-up data are from the multi-center longitudinal 
observational Validation Project38 and TMJ IMPACT Project, respectively. 
Baseline subjects were recruited at the University of Minnesota, University of 
Washington, and University at Buffalo, between 2003 and 2006. Enrollment was 
consecutive until two thirds of the previously calculated sample size was 
achieved, and selective until the closure of the study, to enrich the sample with 
less frequent TMD diagnoses. Thus the Validation Project subject population was 
a convenience sample, consisting of clinical and community TMD cases with the 
full spectrum of TMD signs and symptoms, as well as healthy controls. The 
Validation Project’s methods, including inclusion and exclusion criteria for TMD 
cases and controls, have been previously reported.38  
 
Figure 1 shows the flow diagram of the study sample. 732 subjects enrolled in 
the Validation Project. 8 subjects dropped out or incomplete assessments, and 
724 subjects completed the baseline phase. The study’s examiners could not 
reach a consensus diagnosis for 5 subjects, and 14 subjects were excluded due 
to reported co-morbid pain conditions (e.g., fibromyalgia). The remaining 705 
subjects consisted of 614 TMD cases and 91 controls.38 Of the 614 TMD cases, 
513 subjects had a least one painful TMD diagnosis, including masticatory 
muscle pain (i.e., myofascial pain with and without limited opening) and/or TMJ 
pain (i.e., TMJ arthralgia and TMJ osteoarthritis). In the TMJ IMPACT Project, 
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401 Validation Project subjects who had previously agreed to be contacted were 
recalled. Of the 401 subjects that returned for follow-up, 273 subjects had at least 
one baseline painful TMD diagnosis. Of the 273 potential cases at follow-up, 8 
were excluded from our analyses due to missing data in the baseline SF-12, 2 
were excluded due to having a baseline CPI score of 0, and 4 due to having 
painful TMD diagnoses but a CPI score of 0. One subject was excluded due to 
missing data for the follow-up CPI score. Therefore, our total sample included 
258 subjects. 
 
For the purpose of this study, TMD pain was defined as at least one painful TMD 
diagnosis and a Characteristic Pain Intensity (CPI) score greater than 0.39 
Persistent TMD pain was defined as being present at baseline and at follow-up, 
after 9 years. Inclusion criteria for the present study required complete data for: 
(1) baseline painful TMD diagnosis, (2) baseline CPI score greater than 0, (3) 
baseline SF-12 (PCS and MCS) scores, and (4) follow-up CPI scores. Subjects 
with concurrent painful TMD diagnoses and an inconsistent CPI score of 0 were 
excluded, since the TMD diagnoses required a report of pain in the last month 
and a CPI of 0 indicates no pain in the last 6 months. 
 
Clinical assessment  
At follow-up, subjects had a complete clinical assessment similar to that used at 
baseline in the Validation Project.38 However, one methodological difference 
between baseline and follow-up was that the painful TMD diagnoses at baseline 
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were rendered by the consensus of 2 clinical examiners at each site. At follow-
up, no consensus diagnosis was rendered as each subject saw just one of the 
examiners. The painful TMD diagnoses at follow-up were algorithmically derived 
using the Axis I Diagnostic Criteria for TMD (DC/TMD) protocol.36 The examiners 
at baseline and at follow-up were the same individuals at all 3 study sites. Inter-
rater reliability of examiners, assessed with kappa, was 0.83 for masticatory 
muscle pain and 0.85 for TMJ pain at baseline40 and 0.84 for masticatory muscle 
pain and 0.76 for TMJ pain at follow-up. (Unpublished data) 
 
Baseline predictors 
Baseline questionnaires included the SF-12 version 227 and the JFLS-20 
(JFLS).35,41 The SF-12 is a reliable and valid HRQoL questionnaire28,32,42 used in 
both the clinical and research setting. The SF-12 MCS and PCS scores range 
from 0 to 100 points, and a higher score indicates a better quality of life. Cross-
validation between the SF-12 and the SF-36 demonstrated high correlation 
coefficients of 0.95 for the PCS and 0.97 for the MCS. The SF-12 can also be 
scored in the 8 domain sub-scales; however, their use was not recommended 
after a validation assessment revealed unsatisfactory correlations with SF-36.28  
 
The JFLS is comprised of 20 items each with a 0-10 numerical rating scale of jaw 
functional limitation, where 0 indicates no jaw limitation and 10 indicates severe 
jaw limitation in a specified activity. A “n/a” option is also available for each item, 
and is marked as missing. The JFLS has 3 subscales: mastication, vertical jaw 
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mobility, and verbal and emotional expression, calculated as the average of all 
items in that subscale. A global jaw functional limitation score, on a 0-10 scale, is 
obtained by an average of these three subscales. The JFLS has been validated 
in TMD patients and the reliability coefficients reported were 0.82 for persons and 
0.99 for items.41 The JFLS was developed through item-analysis of the Seattle 
Checklist43 and the Mandibular Functional Impairment Questionnaire44 to 
improve psychometric proprieties of validity, reliability and responsiveness for 
this construct. 
 
Outcome measure 
The CPI questions, from the Graded Chronic Pain Scale,39 were administered at 
baseline and at follow-up. The primary outcome measure for this study is the 
follow-up CPI score, which ranges from 0 to 100, and is calculated based on 
three scales of self-reported pain intensity; a) pain at present time, b) worst pain 
in the last 6 months and c) average pain in the last 6 months. Each of these 
scales ranges from 0 to 10, with 0 = “no pain” and 10 = “pain as bad as it could 
be”. The 3 scores are averaged and multiplied by 10 to obtain the CPI score.  
 
Statistical analyses 
Descriptive statistics are presented for baseline and follow-up data. Two-sample 
t-tests were used for continuous variables and Fisher’s exact tests for categorical 
variables, to determine if there were differences in mean baseline PCS, MCS and 
JFLS scores, as well as other baseline characteristics, between groups with and 
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without follow-up painful TMD diagnoses. Linear regression analysis was used to 
investigate the relationship between baseline PCS, MCS, JFLS global score and 
its sub-scales as predictors of follow-up CPI in single variable and multivariable 
models adjusted for age and sex. 
 
Pearson correlation coefficients and coefficients of determination measured 
associations of baseline PCS, MCS and JFLS with baseline CPI. Additionally, 
tertile analyses were used to evaluate the dose-response relationship of baseline 
PCS, MCS and JFLS global score with follow-up CPI. Tertile analyses were 
adjusted for age and sex, and corrected by Tukey’s method for multiple 
comparisons. Statistical significance was defined as p<0.025 for the two primary 
analyses (baseline PCS and MCS predicting follow-up CPI), i.e., a Bonferroni 
correction (0.05/2) was used for the 2 comparisons. For all other tests, 
considered exploratory, statistical significance was defined as p<0.05. 
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Results 
Of the 258 included subjects with TMD pain at baseline, 186 (72%) had painful 
TMD diagnoses after 9 years. The baseline sample consisted of 88% women, 
with a mean age of 38 years (standard deviation [SD]=13), ranging from 18 to 67 
years. Baseline PCS scores differed significantly between subjects with painful 
TMD diagnoses at follow-up (PCS=49.8, SD=9.5) and subjects without painful 
TMD diagnoses at follow-up [(PCS=52.6, SD=7.0), p=0.009]. MCS and all other 
baseline characteristics did not differ significantly between these two groups, 
except for the JFLS verbal/emotional sub-scale, where subjects with painful TMD 
diagnoses at follow-up had significantly higher JFLS verbal/emotional sub-score 
at baseline (JFLS verbal/emotional=0.9, SD=1.3), compared to subjects without 
painful TMD diagnoses at follow-up [(JFLS verbal/emotional=0.5, SD=1.1), 
p=0.045]. Table 1 presents baseline characteristics of subjects with and without 
painful TMD diagnoses at follow-up are presented. 
 
Table 2 presents follow-up CPI and painful TMD diagnoses. Our primary 
outcome measure was the follow-up TMD pain intensity per the CPI score, which 
had a mean of 28.1 and a SD of 19.9 points, with values ranging from 0 to 86.7 
points on a 0-100 scale. The baseline CPI scores (mean=50.2, SD=20.0 points) 
decreased an average 22.0 points at follow-up, which represents a 43.8% 
decrease in overall TMD pain intensity. At follow-up some subjects reported a 
CPI score greater than 0 for a 6-month reference time frame, but were classified 
as not having a painful TMD diagnoses because the clinical diagnoses were 
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based on pain in the last month. These subjects were not excluded, because this 
is a clinically possible situation, hence the reason Table 2 shows subjects with 
CPI greater than 0 in the group without a follow-up painful TMD diagnosis. 
 
Single variable linear regression analyses 
Table 3 presents the single variable analyses for baseline PCS, MCS and JFLS 
scores as predictors of follow-up CPI. Figures 2-4 graphically display these 
findings. Figure 2 shows the weak negative linear relationship observed between 
baseline PCS and follow-up CPI. One SD (9.0) increase in baseline PCS scores 
was associated with a decrease in follow-up CPI scores of 4.9 points (Standard 
error [SE]=1.2, p<0.001). Compared to the range of CPI scores at follow-up (0.0 
to 86.7), this was a 5.7% decrease, meaning that a better health-related quality 
of life was a weak protective factor. Figure 3 shows the relationship between 
baseline MCS and follow-up CPI, which was not statistically significant. One SD 
(9.1) increase in baseline MCS scores was associated with a decrease in follow-
up CPI scores of 1.4 (SE=1.2, p=0.258). 
 
Figure 4 shows the weak positive linear relationship between baseline JFLS 
global score and follow-up CPI. One SD (1.4) increase in baseline JFLS global 
score was associated with an increase in follow-up CPI scores of 5.0 points 
(SE=1.2, p<0.001). This represents 5.7% of the range of the follow-up CPI 
scores. The 3 baseline JFLS sub-scales were statistically significant predictors of 
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follow-up CPI, but the change they predicted was not greater than predicted by 
the JFLS global score (see Table 3). 
 
Multivariable linear regression model 
The multivariable linear regression model included baseline PCS, MCS and JFLS 
global scores (Table 4). One SD (9.0) increase in baseline PCS scores was 
associated with a decrease in follow-up CPI score of 4.7 points (SE=1.3, 
p<0.001), when controlling for the other variables in the model. One SD (1.4) 
increase in baseline JFLS global score was associated with an increase in follow-
up CPI scores of 3.9 points (SE=1.2, p=0.002) when controlling for the other 
variables in the model. 
 
Baseline cross-sectional analyses 
In a cross-sectional analysis of the baseline data (Table 5), baseline PCS and 
baseline had a weak negative correlation CPI (r=-0.23, p<0.001); baseline PCS 
explained 5.4% of the variance in baseline CPI (r2=0.054). Baseline MCS also 
had a very weak negative correlation with baseline CPI (r=-0.13, p=0.043), 
explaining only 1.6% of the variance in baseline CPI (r2=0.016). Baseline JFLS 
global score had a strong positive correlation with baseline CPI (r=0.53, 
p<0.001), explaining 27.8% of the variance in baseline TMD pain intensity per 
CPI.  
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Tertile analyses 
The tertiles of PCS and JFLS global score differed significantly in follow-up CPI 
scores (Table 6). Figure 5 shows the dose-response relationship between 
baseline PCS tertiles and follow-up CPI. Lower (worse) baseline PCS scores 
were associated with higher (worse) CPI scores at follow-up. The 1st tertile, 
representing individuals with lowest (worst) PCS scores, had a mean follow-up 
CPI score of 30.5 points (SE=2.6), which was significantly higher than the 2nd 
(CPI=22.5, SE=2.5, p=0.023) and 3rd (CPI=18.7, SE=2.4, p<0.001) tertiles. The 
1st and 3rd tertiles differed by 11.7 points in mean follow-up CPI score This 
represents 13.5% of the follow-up CPI score range. The 7.9-point difference 
between 1st and 2nd tertiles is 9.1% of the follow-up CPI score range. Figure 6 
shows the relationship between baseline MCS tertiles and follow-up CPI; MCS 
tertiles did not differ significantly in follow-up CPI (p>0.05). 
Figure 7 shows the dose-response relationship between baseline JFLS global 
score tertiles and follow-up CPI. Higher (worse) baseline JFLS global scores 
were associated with higher (worse) CPI scores at follow-up. The 1st tertile, 
representing individuals with the best jaw function, had a mean follow-up CPI 
score of 17.2 points (SE=2.4), which was significantly lower than the 2nd 
(CPI=25.1, SE=2.4, p=0.019) and 3rd (CPI=31.1, SE=2.6, p<0.001) tertiles. The 
1st and 3rd tertiles differed by 13.9 points in mean follow-up CPI score. This 
represents 16.0% of the follow-up CPI score range. The 7.9-point difference 
between 1st and 2nd tertiles is 9.1% of the follow-up CPI score range (Table 6). 
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Discussion 
The present study found a statistically significant association between baseline 
PCS, MCS and JFLS scores, and follow-up CPI. However, the effects were too 
small to be clinically significant. The correlations between the variables in our 
study are consistent with previous reports.18,20,33,45 Nevertheless, this is the first 
study to assess the clinical significance of these findings. Our results also cohere 
with the current concept of a complex multifactorial etiologic pattern for TMD,45 
where single variables are unlikely to have robust prognostic value. 
 
Clinical Significance 
Assessing and interpreting the clinical significance of research findings is 
extremely important to bridge the gap between research and clinical practice. 
IMMPACT has discussed and reviewed different strategies to determine clinically 
significant changes in outcomes for chronic pain. Recommendations based on a 
literature review suggest that a decrease of 10-20% in self-reported pain intensity 
reflects minimally important improvement, 30% or greater reflects moderately 
important improvement, and 50% reflects substantial improvement.46 In addition, 
data-driven estimates found that a decrease of 2 points or approximately 30% on 
a 0-10 numerical rating scale is considered clinically important to patients with 
osteoarthritis, fibromyalgia, chronic low-back pain, diabetic neuropathy and post-
herpetic neuralgia.47 For acute pain studies, 50% improvement in pain intensity 
has been suggested as the cutoff to evaluate clinical efficacy of analgesics. 48  
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SF-12 literature review 
No previous studies have used baseline SF-12 to predict follow-up pain intensity 
in TMD subjects. A study evaluating multiple putative risk factors for first-onset 
TMD18 found statistically significant adjusted hazard ratios (HR) for 1 SD 
increase in baseline PCS (HR [95%CI]=0.85 [0.74, 0.95], p=0.008) and MCS (HR 
[95%CI]=0.74 [0.66, 0.82], p<0.001). This means that an increase of 1SD in 
baseline PCS scores, decrease the probability of an individual developing first-
onset TMD during the 2.8-year follow-up by 15%. The individual probability is 
decrease by 26% with an increase of 1 SD in baseline MCS scores. The clinical 
significance of these findings was not discussed, but the authors did not include 
SF-12 measures in multivariable models of general-health status as predictor of 
first-onset TMD because it was considered a consequence of other health-
conditions, rather than an independent predictor. 18 In the present study, a 1 SD 
increase in baseline PCS score predicted a reduction in follow-up CPI scores of 
4.9 points (5.7%), which is below suggested standards for clinical significance, 
despite its statistical significance. The change predicted by MCS was less than 
one-third of that observed for PCS and was not statistically or clinically 
significant. 
 
Prior studies have reported a minimal important difference (MID) in the summary 
scores of the SF-12 and SF-36 questionnaires as low as 2-5 points.49-51 
Researchers proposing indexed or distribution-based MIDs have found different 
results. Recommendations include defining MID as 0.5 SD or 1.96 SE, based on 
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observed patterns in the literature, the statistical concept of sample variability, 
and research in psychology that measures the human ability to discriminate 
changes.52-54 Our study found a difference in mean baseline PCS that was 
statistically significant between groups with and without follow-up painful TMD 
diagnoses. A difference of 3.1 points was found in the normalized 0-100 scale of 
the SF-12, which represents 6.1% of the score range (15.7 to 65.4 points), or 
less than 0.5 SD, and is not considered clinically significant (Table 1). 
 
Two cross-sectional studies of subjects with TMD found differences in 3 of the 8 
SF-36 sub-scores, when compared to controls. In the first, general health, vitality, 
and social functioning were statistically significant.24 In the second, physical 
functioning, bodily pain and social functioning were statistically significant.6 PCS 
and MCS scores were not reported. The scoring of the sub-scales, as in the 
summary scores, is based on a 0-100-point scale, where higher scores reflect 
better HRQoL. The magnitude of the differences between groups ranged from 
9.1 to 20.8 points. The differences found in these other studies are greater than 
in the present study, which may be due to comparing TMD subjects with subjects 
from the general population25 or age and sex matched pain-free controls,6 while 
our entire sample had TMD pain at baseline. 
 
JFLS literature review 
IMMPACT recommends the use of disease-specific measures of physical 
functioning when available.33 Disease-specific instruments can assess aspects of 
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physical functioning and pain-imposed limitations associated with the studied 
disorder, disease, or condition that would not be addressed by generic 
measures. Examples of such instruments are the Western Ontario and McMaster 
Universities Arthritis Index (WOMAC)55 and the Roland and Morris Back Pain 
Disability Scale.56 In this sense, the JFLS is an appropriate instrument to assess 
TMD-specific physical functioning. 
 
The JFLS scores were added a posteriori in this study and analyzed as a 
potential predictor of persistent pain, to include disease-specific data in our 
analysis. The JFLS has been found to be significantly associated with TMD when 
TMD cases were compared to pain-free controls.37 That study found that for 
every 1 SD increase in JFLS sub-scores, the odds of being in the TMD group of 
the case-control study increased by 3.0 times for mastication and vertical jaw 
mobility sub-scales (OR [95%CI] = 3.0 [2.6, 3.5]), by 1.6 times for the verbal/ 
emotional expression sub-scale (OR [95%CI] = 1.6 (1.4, 1.8) and by 2.9 times for 
the JFLS global score (OR [95%CI] = 2.9 (2.5, 3,4). Mean JFLS scores for cases 
in this study37 were very similar to the present study. The authors reported mean 
scores of 2.22, 2.22, 0.72 and 1.74 points for mastication, opening, 
verbal/emotional expression, and global score, respectively, compared to mean 
scores of 2.33, 2.50, 0.79 and 1.84 points, respectively, in the present study. 
JFLS scores were not significant predictors of new-onset TMD in a follow-up 
cohort study done by the same group.57  
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This is the first study to report findings on the JFLS as a predictor of persistent 
TMD pain. Baseline JFLS global score and its sub-scales were statistically 
significant predictors of follow-up CPI in a linear regression analysis adjusted for 
age and sex. Nevertheless, the magnitude of the association was effectively the 
same as for baseline PCS, for which a 1 SD change was associated with a 5.7% 
change in follow-up CPI scores for the JFLS global score. As argued above, 
these likely do not represent large enough effects to be clinically significant. 
 
Multivariable analysis 
When baseline PCS, MCS and JFLS global scores were combined in a 
multivariable model, PCS and JFLS remained statistically significant. Especially 
for the baseline PCS score, the effect size was largely maintained, changing from 
-4.9 to -4.7 when controlling for the other variables in the model. The stability of 
the effect despite adjusting for potential confounders can be interpreted as a sign 
that the observed effect is in fact present. The magnitude and the direction of 
change in effect after partial adjustment for confounding can be used to make 
inferences about the actual effect.58 Nonetheless, it reinforces the lack of clinical 
significance, because the true effect would be highly unlikely to move in the 
opposite direction, towards a greater magnitude.58  
 
Sample selection 
The original Validation Project was not designed to address the aims of the 
present study, but it followed specific guidelines: the statement for reporting 
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studies of diagnostic accuracy (STARD).59 These guidelines recommend that, 
when developing diagnostic criteria, the first step is to use a sample of individuals 
with the target condition and free of significant co-morbidities. According to the 
trend observed in the tertile analyses in the present study, subjects with worse 
baseline PCS and JFLS scores presented a greater change in follow-up CPI 
scores. If that trend extended beyond the range of our data, it is possible that the 
effect sizes would reach clinical significance in subjects with higher baseline 
impairment in HRQoL and jaw function. While it seems plausible that, in subjects 
with non-TMD pain and other medical co-morbidities, baseline PCS and JFLS 
scores could potentially be worse, the predictive value of baseline PCS and JFLS 
for follow-up CPI in such population is unknown. 
 
9- year follow-up and scope of evaluation 
The long interval between baseline and follow-up data may account for difficulty 
in predicting the outcome of persistent pain. The status of subjects during this 
follow-up period is unknown, and treatments received between evaluations were 
not considered in the analyses. It has been suggested that a 1-month recall 
period allows for a better self-reported pain intensity rating,60 but the 6-month 
period is also considered acceptable.42,61 In a study of migraineurs, self-report of 
pain intensity (0-10 scale) over the 3 previous months had a high correlation 
(r=0.74) with a daily pain diary, which was considered the reference standard.62  
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In our case, the 6-month reference was used since this was the period used in 
the original questionnaire38 and in the Validation Project.38 Also, considering the 
fluctuating nature of TMD pain, a 6-month reference period is thought to provide 
a better coverage of the time between visits, especially if the interval between 
follow-ups is over a long period like the present study. The long interval between 
the two measurement times introduces a level of uncertainty; however, the 
baseline cross-sectional analysis shows that stronger associations may never 
have been present (Table 5). The strength of the associations between putative 
baseline predictors and baseline CPI were not dramatically different than in the 
longitudinal analyses, which supports the results of this study. 
 
The TMJ IMPACT Project, which provided the follow-up data for this study, 
recalled only 401 subjects who had previously agreed to be contacted for 
reevaluation, out of the 614 cases and 91 controls from the Validation Project. 
Thus, selective follow-up may have introduced bias into the analysis. Although 15 
of 273 subjects were excluded due to inconsistent or missing data, these 
represent only 5% of the potential sample and are unlikely to introduced major 
bias into the results. Finally, the present study did not account for a series of 
other potential confounding factors that could be used in the multivariable 
analysis for persistent TMD pain, such as TMD pain chronicity, oral behaviors, 
somatization, depression and anxiety.36  
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When evaluating patient reported outcomes (PROs) of jaw pain, jaw function and 
quality of life, these outcomes should be self-reported, without interpretation of 
the patient’s response by a clinician or anyone else.63 PROs, and specifically 
HRQoL, have become important constructs in patient-centered research and 
clinical practice. Some authors argue that “[t]he ultimate goal of health care is to 
restore or preserve functioning and well-being related to health, that is health-
related quality of life.”64 Nevertheless, assessment of PROs remains inherently 
subject to the limitations of the instruments that measure them. If the instrument 
does not measure the desired construct adequately, then non-significant study 
results could arise from its shortcomings. Validity assessment of questionnaires 
typically involves construct and not criterion validity.65 Construct validity is based 
on how consistently a particular measure relates to theoretical hypotheses about 
the concepts being measured.66 For instance, subjects with more severe health 
conditions, presumed to have higher HRQoL impairment, should consistently 
obtain worse HRQoL scores than healthy subjects or subjects with milder health 
conditions. The SF-12 construct validity has been assessed by comparing scores 
of subjects in different groups. SF-12 scores were able to discriminate between 
these groups, known to differ in presence and seriousness of physical and 
mental health conditions.28,32 Concurrent validity for the SF-12 was also 
established versus the SF-36 for PCS and MCS,28,32 and versus the EuroQol EQ-
5D, another HRQoL questionnaire.58 
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Conclusions 
This is the first study to examine both the statistical and clinical significance of 
the longitudinal association of HRQoL and jaw functional limitation with persistent 
TMD pain intensity. In subjects with TMD pain, baseline PCS and JFLS scores 
were statistically significant predictors of CPI at a 9-year follow-up. However, the 
magnitude of the effects is small and not clinically significant. Future studies 
should routinely report the clinical significance of their findings to bridge the 
current gap between research findings and their application in the clinical setting. 
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Illustrations 
Figure 1: Flow Diagram of Study Subjects 
CPI: Characteristic Pain Intensity, Dx: Diagnosis. 
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Table 1: Baseline Characteristics of Subjects With and Without Follow-up Painful 
TMD Diagnoses 
Variable Category Total 
Follow-up              
Painful  
TMD Dx  
Follow-up                              
No Painful 
TMD Dx p-value 
(n=258) (n=186) (n=72) 
Sex 
Male n(%) 31 (12.0) 18 (9.7) 13 (18.1) 0.086 
Female n(%) 227 (88.0) 168 (90.3) 59 (81.9)  
Age                        
(years) 
Mean (SD) 37.8 (13.0) 38.4 (13.2) 36.2 (12.7) 0.231 
(Min, Max) (18.0, 67.0) (18.0, 67.0) (18.0, 65.0)  
Baseline CPI                 
0-100 
Total n 258 186 72 0.322 
Mean (SD) 50.2 (20.0) 51.0 (19.5) 48.1 (21.4)  
(Min, Max) (6.7, 100.0) (10.0, 93.3) (6.7, 100.0)  
Baseline SF-12 
PCS                      
0-100 
Total n 258 186 72 0.009 
Mean (SD) 50.6 (8.9) 49.8 (9.5) 52.6 (7.0)  
(Min, Max) (15.7, 65.4) (24.1, 65.4) (15.7, 64.5)  
Baseline SF-12 
MCS                                 
0-100 
Total n 258 186 72 0.166 
Mean (SD) 49.6 (9.1) 49.1 (9.21) 50.8 (8.7)  
(Min, Max) (22.8, 67.3) (22.8, 65.2) (23.3, 67.3)  
Baseline Painful 
TMD Diagnosis                           
n(%) 
Total n 258 186 72 0.353 
Articular Pain 35 (13.6) 26 (14.0) 9 (12.5)  
Muscular Pain 3 (1.2) 1 (0.5) 2 (2.8)  
Both 220 (85.3) 159 (85.5) 61 (84.7)  
Baseline JFLS 
Global Score 
0-10 
Total n 249 181 68 0.165 
Mean (SD) 1.8 (1.4) 1.9 (1.4) 1.6 (1.5)  
(Min, Max) (0.0, 8.0) (0.0, 6.5) (0.00, 8.0)  
Baseline JFLS 
Mastication  
Sub-scale (0-10) 
Total n 257 186 71 0.393 
Mean (SD) 2.3 (1.8) 2.4 (1.7) 2.2 (1.9)  
(Min, Max)  (0.0, 8.3)  (0.0, 8.3)  (0.0, 7.8)  
Baseline JFLS 
Opening 
Sub-scale (0-10) 
Total n 255 184 71  0.779 
Mean (SD) 2.5 (2.0) 2.5 (1.9) 2.6 (2.3)  
(Min, Max)  (0.0, 9.0)  (0.0, 7.3)  (0.0, 9.0)  
Baseline JFLS 
Verbal/Emotional 
Sub-scale (0-10) 
Total n 250 182 68  0.045 
Mean (SD) 0.8 (1.2) 0.9 (1.3) 0.5 (1.1)  
(Min, Max)  (0.0, 7.3)  (0.0, 7.3)  (0.0, 7.1)  
CPI: Characteristic Pain Intensity, PCS: Physical Component Summary, MCS: Mental 
Component Summary, JFLS: Jaw Functional Limitation Scale, Dx: Diagnosis. SD: Standard 
Deviation. 
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Table 2: Follow-up Characteristic Pain Intensity and Painful TMD Diagnoses 
Variable Category 
Total 
Follow-up 
Painful  
TMD Dx 
Follow-up                              
No Painful 
TMD Dx 
(n=258) (n=186)  (n=72) 
Follow-up CPI                  
0-100 
Total n 258 186 72 
Mean (SD) 28.1 (19.9) 34.5 (18.0) 11.6 (14.2) 
(Min, Max) (0.0, 86.7) (6.7, 86.7) (0.0, 66.7) 
Follow-up 
Painful TMD 
Diagnoses                            
n(%)                        
Total n 258 186 72 
None 72 (27.9) 0 72 (100.0) 
TMJ Pain Only 35 (13.6) 35(18.8) 0 
Muscle Pain Only  5 (1.9) 5 (2.7) 0 
Both 146 (56.6) 146 (78.5) 0 
CPI: Characteristic Pain Intensity, Dx: Diagnosis. 
 
Table 3: Change in Follow-up Characteristic Pain Intensity Predicted by 1 SD 
Increase in Baseline Predictors 
Change in Follow-up CPI (Single Variable Analyses) 
Predictor Comparison  Estimate (SE) p-value 
Baseline SF-12 PCS  1 SD (9.0)  -4.9(1.2) <0.001 
Baseline SF-12 MCS  1 SD (9.1) -1.4(1.2) 0.258 
Baseline JFLS Global Score 1 SD (1.4) 5.0 (1.2) <0.001 
Baseline JFLS Mastication Sub-scale 1 SD (1.8) 4.3(1.2) <0.001 
Baseline JFLS Opening Sub-scale 1 SD (2.0) 2.6(1.2) 0.035 
Baseline JFLS Verbal/Emotional Sub-scale  1 SD (1.2) 3.0(0.8) <0.001 
CPI: Characteristic Pain Intensity, PCS: Physical Component Summary, MCS: Mental 
Component Summary, JFLS: Jaw Functional Limitation Scale, SD: Standard Deviation, SE: 
Standard Error. 
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Figure 2: Linear Relationship Between Baseline SF-12 Physical Component 
Summary and Follow-up Characteristic Pain Intensity 
 
 
 
 
 
 
 
 
 
 
 
 
1 SD (9.0) increase in baseline PCS was associated with a 4.9-point decrease in follow-
up CPI scores [(SE=1.2), p<0.001]. 
PCS: Physical Component Summary, CPI: Characteristic Pain Intensity, SD: Standard Deviation, 
SE: Standard Error. 
 
Figure 3: Linear Relationship Between Baseline SF-12 Mental Component 
Summary and Follow-up Characteristic Pain Intensity  
 
 
 
 
 
 
 
 
 
There was not a significant linear relationship between baseline MCS and follow-up CPI 
(p=0.258). 
MCS: Mental Component Summary, CPI: Characteristic Pain Intensity, SD: Standard Deviation. 
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Figure 4: Linear Relationship Between Baseline Jaw Functional Limitation Scale 
and Follow-up Characteristic Pain Intensity 
1 SD (1.4) increase in baseline JFLS scores was associated with a 5.0-point increase in 
follow-up CPI scores [(SE=1.2), p<0.001]. 
JFLS: Jaw Functional Limitation Scale, CPI: Characteristic Pain Intensity, SD: Standard 
Deviation, SE: Standard Error. 
 
Table 4: Multivariable Model for Predicting Follow-up Characteristic Pain Intensity 
Estimates and p-values reflect the effect of 1 SD increase in baseline predictors when 
controlling for all other variables in the model.  
CPI: Characteristic Pain Intensity, PCS: Physical Component Summary, MCS: Mental 
Component Summary, JFLS: Jaw Functional Limitation Scale, SD: Standard Deviation, SE: 
Standard Error. 
  
Change in Follow-up CPI (Multivariable Analysis) 
Predictor Comparison  Estimate (SE) p-value 
Baseline SF-12 PCS  1 SD (9.0)  -4.7 (1.3)  <0.001 
Baseline SF-12 MCS  1 SD (9.1) -2.2 (1.3)  0.077 
Baseline JFLS Global Score 1 SD (1.4) 3.9 (1.2)  0.002 
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Table 5: Association between Baseline Physical Component Summary, Mental 
Component Summary and Jaw Functional Limitation Scale Global 
Score, and Baseline Characteristic Pain Intensity  
Pearson Correlation Coefficient (r) with Baseline CPI 
Variable n r p-value r2 
Baseline SF-12 PCS 258 -0.23 <0.001 0.054 
Baseline SF-12 MCS 258 -0.13 0.043 0.016 
Baseline JFLS Global Score 249 0.53 <0.001 0.278 
PCS: Physical Component Summary, MCS: Mental Component Summary, JFLS: Jaw Functional 
Limitation Scale, CPI: Characteristic Pain Intensity, r: Pearson Correlation Coefficient, r2: 
Coefficient of Determination. 
 
 
 
Table 6: Mean Follow-up Characteristic Pain Intensity by Baseline Physical 
Component Summary, Mental Component Summary and Jaw 
Functional Limitation Scale Global Score Tertiles 
Mean Follow-up CPI (SE) p-value 
Predictor 1st tertile 2nd tertile 3rd tertile 1st vs. 2nd  1st vs. 3rd  2nd vs. 3rd  
SF-12 PCS 
Tertiles 
30.5 (2.6) 22.5 (2.5) 18.7 (2.4)  0.023  <0.001  0.379 
SF-12 MCS 
Tertiles 
27.2 (2.5) 21.2 (2.5) 22.4 (2.5)  0.103  0.241  0.904 
JFLS Global 
Score Tertiles 
17.2 (2.4) 25.1 (2.4) 31.1 (2.6)  0.019 <0.001  0.107 
Lower tertiles represent worse quality of life for PCS/MCS and lower jaw functional 
limitation (better jaw function) for JFLS. 
CPI: Characteristic Pain Intensity, PCS: Physical Component Summary, MCS: Mental 
Component Summary, JFLS: Jaw Functional Limitation Scale, SE: Standard Error. 
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Figure 5: Mean Follow-up Characteristic Pain Intensity (95% CI) by Baseline   
SF-12 Physical Component Summary Tertiles 
Differences between 1st and 3rd (p<0.001), as well as 1st and 2nd (p=0.023) tertiles were 
statistically significant. 
CPI: Characteristic Pain Intensity, PCS: Physical Component Summary, CI: Confidence Interval. 
 
 
Figure 6: Mean Follow-up Characteristic Pain Intensity (95% CI) by Baseline   
SF-12 Mental Component Summary Tertiles 
There were no statistically significant differences between tertiles. (p>0.05)  
CPI: Characteristic Pain Intensity, MCS: Mental Component Summary, CI: Confidence Interval. 
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Figure 7: Mean Follow-up Characteristic Pain Intensity (95% CI) by Baseline Jaw 
Functional Limitation Scale Global Score Tertiles 
Differences between 1st and 3rd (p<0.001), as well as 1st and 2nd (p=0.019) tertiles were 
statistically significant.  
CPI: Characteristic Pain Intensity, JFLS: Jaw Functional Limitation Scale, CI: Confidence Interval. 
 
 
 
 
 
 
 
 
Baseline JFLS Global Score tertiles F
ol
lo
w
-u
p 
C
ha
ra
ct
er
is
tic
 P
ai
n 
In
te
ns
ity
 
  29 
Bibliography 
1. Okeson JP, de Kanter RJ. Temporomandibular disorders in the medical practice. J Fam Pract. 
1996;43(4):347-356. 
2. LeResche L. Epidemiology of temporomandibular disorders: Implications for the investigation 
of etiologic factors. Crit Rev Oral Biol Med. 1997;8(3):291-305. 
3. NIDCR - National Institute of Dental and Craniofacial Research. Find data by topic: Facial 
pain. http://www.nidcr.nih.gov/DataStatistics/FindDataByTopic/FacialPain/. Updated 20142014. 
4. NIH Medline Plus. Chronic pain: Symptoms, diagnosis, & treatment. 
https://www.nlm.nih.gov/medlineplus/magazine/issues/spring11/articles/spring11pg5-6.html. 
Updated Spring, 2011. Accessed 10/21, 2015. 
5. Quartana PJ, Buenaver LF, Edwards RR, Klick B, Haythornthwaite JA, Smith MT. Pain 
catastrophizing and salivary cortisol responses to laboratory pain testing in temporomandibular 
disorder and healthy participants. J Pain. 2010;11(2):186-194. doi: 10.1016/j.jpain.2009.07.008 
[doi]. 
6. Johnson J, Johansson M, Ryden A, Houltz E, Finizia C. The impact of trismus on health-
related quality of life and mental health. Head Neck. 2014. doi: 10.1002/hed.23816 [doi]. 
7. Dahlstrom L, Carlsson GE. Temporomandibular disorders and oral health-related quality of 
life. A systematic review. Acta Odontol Scand. 2010;68(2):80-85. doi: 
10.3109/00016350903431118 [doi]. 
8. De Leeuw R, Bertoli E, Schmidt JE, Carlson CR. Prevalence of traumatic stressors in patients 
with temporomandibular disorders. J Oral Maxillofac Surg. 2005;63(1):42-50. doi: 
S027823910401273X [pii]. 
9. Epker J, Gatchel RJ. Coping profile differences in the biopsychosocial functioning of patients 
with temporomandibular disorder. Psychosom Med. 2000;62(1):69-75. 
  30 
10. Zakrzewska JM. Multi-dimensionality of chronic pain of the oral cavity and face. J Headache 
Pain. 2013;14(1):37-2377-14-37. doi: 10.1186/1129-2377-14-37 [doi]. 
11. Velly AM, Look JO, Carlson C, et al. The effect of catastrophizing and depression on chronic 
pain--a prospective cohort study of temporomandibular muscle and joint pain disorders. Pain. 
2011;152(10):2377-2383. doi: 10.1016/j.pain.2011.07.004 [doi]. 
12. McBeth J, Macfarlane GJ, Benjamin S, Silman AJ. Features of somatization predict the onset 
of chronic widespread pain: Results of a large population-based study. Arthritis Rheum. 
2001;44(4):940-946. doi: 10.1002/1529-0131(200104)44:4<940::AID-ANR151>3.0.CO;2-S 
[doi]. 
13. Lacey RJ, Lewis M, Sim J. Piecework, musculoskeletal pain and the impact of workplace 
psychosocial factors. Occup Med (Lond). 2007;57(6):430-437. doi: kqm048 [pii]. 
14. Linton SJ. A review of psychological risk factors in back and neck pain. Spine (Phila Pa 
1976). 2000;25(9):1148-1156. 
15. Melloh M, Elfering A, Egli Presland C, et al. Identification of prognostic factors for 
chronicity in patients with low back pain: A review of screening instruments. Int Orthop. 
2009;33(2):301-313. doi: 10.1007/s00264-008-0707-8 [doi]. 
16. Walton DM, Carroll LJ, Kasch H, et al. An overview of systematic reviews on prognostic 
factors in neck pain: Results from the international collaboration on neck pain (ICON) project. 
Open Orthop J. 2013;7:494-505. doi: 10.2174/1874325001307010494 [doi]. 
17. Zakrzewska JM. Differential diagnosis of facial pain and guidelines for management. Br J 
Anaesth. 2013;111(1):95-104. doi: 10.1093/bja/aet125 [doi]. 
18. Sanders AE, Slade GD, Bair E, et al. General health status and incidence of first-onset 
temporomandibular disorder: The OPPERA prospective cohort study. J Pain. 2013;14(12 
Suppl):T51-62. doi: 10.1016/j.jpain.2013.06.001 [doi]. 
  31 
19. Fillingim RB, Ohrbach R, Greenspan JD, et al. Psychological factors associated with 
development of TMD: The OPPERA prospective cohort study. J Pain. 2013;14(12 Suppl):T75-
90. doi: 10.1016/j.jpain.2013.06.009 [doi]. 
20. Fillingim RB, Ohrbach R, Greenspan JD, et al. Potential psychosocial risk factors for chronic 
TMD: Descriptive data and empirically identified domains from the OPPERA case-control study. 
J Pain. 2011;12(11 Suppl):T46-60. doi: 10.1016/j.jpain.2011.08.007 [doi]. 
21. Aggarwal VR, Macfarlane GJ, Farragher TM, McBeth J. Risk factors for onset of chronic 
oro-facial pain--results of the north cheshire oro-facial pain prospective population study. Pain. 
2010;149(2):354-359. doi: 10.1016/j.pain.2010.02.040 [doi]. 
22. Lipton RB, Liberman JN, Kolodner KB, Bigal ME, Dowson A, Stewart WF. Migraine 
headache disability and health-related quality-of-life: A population-based case-control study from 
england. Cephalalgia. 2003;23(6):441-450. doi: 546 [pii]. 
23. Picavet HS, Hoeymans N. Health related quality of life in multiple musculoskeletal diseases: 
SF-36 and EQ-5D in the DMC3 study. Ann Rheum Dis. 2004;63(6):723-729. doi: 
10.1136/ard.2003.010769 [doi]. 
24. Salaffi F, De Angelis R, Stancati A, Grassi W, MArche Pain, Prevalence INvestigation Group 
(MAPPING) study. Health-related quality of life in multiple musculoskeletal conditions: A cross-
sectional population based epidemiological study. II. the MAPPING study. Clin Exp Rheumatol. 
2005;23(6):829-839. doi: 1720 [pii]. 
25. Tjakkes GH, Reinders JJ, Tenvergert EM, Stegenga B. TMD pain: The effect on health 
related quality of life and the influence of pain duration. Health Qual Life Outcomes. 2010;8:46-
7525-8-46. doi: 10.1186/1477-7525-8-46 [doi]. 
26. Barros Vde M, Seraidarian PI, Cortes MI, de Paula LV. The impact of orofacial pain on the 
quality of life of patients with temporomandibular disorder. J Orofac Pain. 2009;23(1):28-37. 
27. Optum™. SF-12® Health survey. https://www.optum.com/optum-outcomes/what-we-
do/health-surveys/sf-12v2-health-survey.html. 
  32 
28. Ware J,Jr, Kosinski M, Keller SD. A 12-item short-form health survey: Construction of scales 
and preliminary tests of reliability and validity. Med Care. 1996;34(3):220-233. 
29. Ware JE,Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. 
conceptual framework and item selection. Med Care. 1992;30(6):473-483. 
30. Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF. Migraine, quality of life, 
and depression: A population-based case-control study. Neurology. 2000;55(5):629-635. 
31. Mas AJ, Carmona L, Valverde M, Ribas B, EPISER Study Group. Prevalence and impact of 
fibromyalgia on function and quality of life in individuals from the general population: Results 
from a nationwide study in spain. Clin Exp Rheumatol. 2008;26(4):519-526. doi: 2383 [pii]. 
32. Cheak-Zamora NC, Wyrwich KW, McBride TD. Reliability and validity of the SF-12v2 in 
the medical expenditure panel survey. Qual Life Res. 2009;18(6):727-735. doi: 10.1007/s11136-
009-9483-1 [doi]. 
33. Bair E, Ohrbach R, Fillingim RB, et al. Multivariable modeling of phenotypic risk factors for 
first-onset TMD: The OPPERA prospective cohort study. J Pain. 2013;14(12 Suppl):T102-15. 
doi: 10.1016/j.jpain.2013.09.003 [doi]. 
34. Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical 
trials: IMMPACT recommendations. Pain. 2005;113(1-2):9-19. doi: S0304-3959(04)00440-3 
[pii]. 
35. Ohrbach R, Larsson P, List T. The jaw functional limitation scale: Development, reliability, 
and validity of 8-item and 20-item versions. J Orofac Pain. 2008;22(3):219-230. 
36. Schiffman E, Ohrbach R, Truelove E, et al. Diagnostic criteria for temporomandibular 
disorders (DC/TMD) for clinical and research applications: Recommendations of the international 
RDC/TMD consortium network* and orofacial pain special interest groupdagger. J Oral Facial 
Pain Headache. 2014;28(1):6-27. doi: 10.11607/jop.1151 [doi]. 
37. Ohrbach R, Fillingim RB, Mulkey F, et al. Clinical findings and pain symptoms as potential 
risk factors for chronic TMD: Descriptive data and empirically identified domains from the 
  33 
OPPERA case-control study. J Pain. 2011;12(11 Suppl):T27-45. doi: 
10.1016/j.jpain.2011.09.001 [doi]. 
38. Schiffman EL, Truelove EL, Ohrbach R, et al. The research diagnostic criteria for 
temporomandibular disorders. I: Overview and methodology for assessment of validity. J Orofac 
Pain. 2010;24(1):7-24. 
39. Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic pain. Pain. 
1992;50(2):133-149. doi: 0304-3959(92)90154-4 [pii]. 
40. Schiffman EL, Ohrbach R, Truelove EL, et al. The research diagnostic criteria for 
temporomandibular disorders. V: Methods used to establish and validate revised axis I diagnostic 
algorithms. J Orofac Pain. 2010;24(1):63-78. 
41. Ohrbach R, Granger C, List T, Dworkin S. Preliminary development and validation of the jaw 
functional limitation scale. Community Dent Oral Epidemiol. 2008;36(3):228-236. doi: 
10.1111/j.1600-0528.2007.00397.x [doi]. 
42. Ohrbach R, Turner JA, Sherman JJ, et al. The research diagnostic criteria for 
temporomandibular disorders. IV: Evaluation of psychometric properties of the axis II measures. 
J Orofac Pain. 2010;24(1):48-62. 
43. Dworkin SF, LeResche L. Research diagnostic criteria for temporomandibular disorders: 
Review, criteria, examinations and specifications, critique. J Craniomandib Disord. 
1992;6(4):301-355. 
44. Stegenga B, de Bont LG, de Leeuw R, Boering G. Assessment of mandibular function 
impairment associated with temporomandibular joint osteoarthrosis and internal derangement. J 
Orofac Pain. 1993;7(2):183-195. 
45. Slade GD, Fillingim RB, Sanders AE, et al. Summary of findings from the OPPERA 
prospective cohort study of incidence of first-onset temporomandibular disorder: Implications and 
future directions. J Pain. 2013;14(12 Suppl):T116-24. doi: 10.1016/j.jpain.2013.09.010 [doi]. 
  34 
46. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment 
outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9(2):105-
121. doi: S1526-5900(07)00899-1 [pii]. 
47. Farrar JT, Young JP,Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes 
in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 
2001;94(2):149-158. doi: S0304-3959(01)00349-9 [pii]. 
48. Moore A, Moore O, McQuay H, Gavaghan D. Deriving dichotomous outcome measures from 
continuous data in randomised controlled trials of analgesics: Use of pain intensity and visual 
analogue scales. Pain. 1997;69(3):311-315. doi: S0304-3959(96)03306-4 [pii]. 
49. Ingram M, Choi YH, Chiu CY, et al. Use of the minimal clinically important difference 
(mcid) for evaluating treatment outcomes with tmjmd patients: A preliminary study(). J Appl 
Biobehav Res. 2011;16(3-4):148-166. doi: 10.1111/j.1751-9861.2011.00068.x [doi]. 
50. Angst F, Aeschlimann A, Stucki G. Smallest detectable and minimal clinically important 
differences of rehabilitation intervention with their implications for required sample sizes using 
WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the 
lower extremities. Arthritis Rheum. 2001;45(4):384-391. doi: 10.1002/1529-
0131(200108)45:4<384::AID-ART352>3.0.CO;2-0 [doi]. 
51. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with 
chronic conditions. results from the medical outcomes study. JAMA. 1989;262(7):907-913. 
52. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of 
life: The remarkable universality of half a standard deviation. Med Care. 2003;41(5):582-592. 
doi: 10.1097/01.MLR.0000062554.74615.4C [doi]. 
53. Wyrwich KW, Nienaber NA, Tierney WM, Wolinsky FD. Linking clinical relevance and 
statistical significance in evaluating intra-individual changes in health-related quality of life. Med 
Care. 1999;37(5):469-478. 
  35 
54. Ware JE,Jr, Bayliss MS, Rogers WH, Kosinski M, Tarlov AR. Differences in 4-year health 
outcomes for elderly and poor, chronically ill patients treated in HMO and fee-for-service 
systems. results from the medical outcomes study. JAMA. 1996;276(13):1039-1047. 
55. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of 
WOMAC: A health status instrument for measuring clinically important patient relevant 
outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J 
Rheumatol. 1988;15(12):1833-1840. 
56. Roland M, Morris R. A study of the natural history of back pain. part I: Development of a 
reliable and sensitive measure of disability in low-back pain. Spine (Phila Pa 1976). 
1983;8(2):141-144. 
57. Ohrbach R, Bair E, Fillingim RB, et al. Clinical orofacial characteristics associated with risk 
of first-onset TMD: The OPPERA prospective cohort study. J Pain. 2013;14(12 Suppl):T33-50. 
doi: 10.1016/j.jpain.2013.07.018 [doi]. 
58. Savitz DA. Confounding: Assess consequences of innacurate confounder measurement. In: 
Interpreting epidemiologic evidence: Strategies for study design and analysis. New York, NY: 
Oxford University Press; 2003:146-152. 
59. Bossuyt PM, Reitsma JB, Bruns DE, et al. The STARD statement for reporting studies of 
diagnostic accuracy: Explanation and elaboration. Ann Intern Med. 2003;138(1):W1-12. doi: 
200301070-00012-W1 [pii]. 
60. Underwood MR, Barnett AG, Vickers MR. Evaluation of two time-specific back pain 
outcome measures. Spine (Phila Pa 1976). 1999;24(11):1104-1112. 
61. Von Korff M. Assessment of chronic pain in epidemiological and health services research. In: 
Turk DC, Melzack R, eds. Handbook of pain assessment. 3rd ed. New York, NY: Guilford Press; 
2011:455-471. 
62. Stewart WF, Lipton RB, Simon D, Liberman J, Von Korff M. Validity of an illness severity 
measure for headache in a population sample of migraine sufferers. Pain. 1999;79(2-3):291-301. 
  36 
63. ISOQOL - International Society of Quality of Life Research. What is health-related quality of 
life research. http://www.isoqol.org/about-isoqol/what-is-health-related-quality-of-life-research. 
Accessed 10/04, 2015. 
64. Osoba D, King M. Meaningful differences. In: Fayers P, Hays RD, eds. Assessing quality of 
life in clinical trials. New York, NY: Oxford Press; 2005:244-257. 
65. Feeny D, Furlong W, Mulhern RK, Barr RD, Hudson M. A framework for assessing health-
related quality of life among children with cancer. Int J Cancer Suppl. 1999;12:2-9. doi: 
10.1002/(SICI)1097-0215(1999)83:12+<2::AID-IJC2>3.0.CO;2-M [pii]. 
66. Cronbach LJ, Meehl PE. Construct validity in psychological tests. Psychol Bull. 
1955;52(4):281-302. 
  
